Abstract:To describe the experience in a recently created ocular graft-versus-host disease unit in a tertiary hospital and to detail ocular surface features and complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT). This retrospective study included all patients who underwent allo-HSCT, with or without chronic GVHD and were being monitored in the Hematopoietic Stem Cell Transplantation Unit in the UNICAMP Clinical Hospital (Campinas, Sao Paulo, Brazil) from 2015 to 2020. Patients were concomitantly evaluated by hematology and ophthalmology teams of the Ocular GVHD Unit. Hematologists performed a comprehensive systemic evaluation searching and grading mouth, skin, lungs, gastrointestinal tract, liver and genitalia GVHD. While ophthalmologists evaluated ocular symptoms through specific questionnaire (Ocular Surface Disease Index-OSDI) and a protocol of distinct ocular surface parameters for dry eye disease (1) and ocular complications, which encompassed meniscometry, non-invasive tear break-up time (NITBUT) measurement, conjunctival hyperemia quantification, meibography, fluorescein and lissamine staining and Schirmer's test. Patients were diagnosed with chronic GVHD using the National Institutes of Health (NIH) Consensus Criteria for Chronic Graft-versus-Host Disease. The International Chronic Ocular GVHD Consensus Group (ICOGCG) score was obtained at the onset of ocular disease presentation or afterwards. A total of 82 patients underwent allo-HSCT (97.6% full matched and 2.4% haploidentical), mainly for cases of leukemia and 73.2% had chronic GVHD. Mean onset time for chronic GVHD was 232 ± 7.75 days. The mouth, skin, and eyes were the main organs involved (63%, 50%, and 48%, respectively). Symptom scores and all ocular surface parameters differ in patients with and without chronic GVHD and along different timepoints of the follow-up. Ocular complications mostly involved were severe DED and meibomian gland dysfunction, conjunctival scarring, cataract and infections resulting in keratitis and corneal perforation. As therapeutic strategies, 73% patients received preservative-free lubricants, 27% autologous serum, 48% topical steroids, 27% oral tetracycline derivatives, 22% mucolytic eye drops and 3 patients needed bandage contact lens. Ocular GVHD is a complex and challenging disease with varied manifestations, resulting in a broad range of ocular test endpoints, and inconsistent treatment responses. The main ocular presentations were dry eye, meibomian gland dysfunction and cataracts. The therapeutic approach often involves topical steroids and autologous serum tears. It is important to monitor these patients closely, so the ocular GVHD Unit may improve the care, providing prompt identification of ocular manifestations and faster treatment of complications.

Ocular manifestations and quality of life in patients after hematopoietic stem cell transplantation

Vision-specific and cancer-specific quality of life in ocular graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Correlative factors of ocular surface lesions after allogeneic hematopoietic stem cell transplantation: A retrospective study

Sleep Quality in Patients With Ocular Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Clinical Characteristics and Prognostic Factors of Nephrotic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation

Advances in the ocular complications after hematopoietic stem cell transplantation

Ocular surface indicators and biomarkers in chronic ocular graft-versus-host disease: a prospective cohort study

Ocular screening for chronic graft-versus-host disease in patients with allogeneic hematopoietic stem cell transplant

Ophthalmologic findings and complications before and after hematopoietic stem cell transplantation: single-center study

Ocular graft host disease after allogeneic stem cell transplant: unique risk factors and outcomes

A plethora of ocular surface manifestations in a multidisciplinary ocular graft-versus-host disease unit

Health Related Quality of Life among Patients with Chronic Graft-Versus-host Disease in China.

Delayed diagnosis of ocular graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

A nomogram model for predicting ocular GVHD following allo-HSCT based on risk factors

“Window of Opportunity” in Ocular Graft-Versus-Host Disease Treatment: Results of a Longitudinal Study and Case Reports

Diagnosis and treatment of ocular graft-versus-host disease

Posterior segment complications and the risk factors after allogeneic hematopoietic stem cell transplantation

Understanding Ocular Graft-versus-Host Disease to Facilitate an Integrated Multidisciplinary Approach

Prevalence and risk factors associated with development of ocular GVHD defined by NIH consensus criteria

Tear inflammatory mediators and protein in eyes of post allogenic hematopoeitic stem cell transplant patients

[Evaluation of differences in quality of life in patients with chronic graft-versus-host disease]